Labcorp (LH) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Revvity (RVTY) has outperformed Labcorp (LH) over the past year, gaining 65.8% versus a gain of 13.2%. Over five years, LH leads with a +34.7% price change compared with -10.4% for RVTY. Labcorp is the larger company by market cap ($25.55 billion vs $17.29 billion), about 1.5 times the size.
On valuation, Labcorp trades at a lower forward P/E (15.9x vs 26.3x for Revvity). Labcorp offers the higher dividend yield (0.91% vs 0.18%). Revvity converts more of its revenue into profit, with a net margin of 8.4% versus 6.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LH | RVTY |
|---|---|---|
| Share price | $315.09 | $154.98 |
| Market cap | $25.55B | $17.29B |
| 1-day change | +0.28% | +1.85% |
| YTD return | +25.24% | +57.27% |
| 1-year return | +13.22% | +65.81% |
| 5-year return | +34.66% | -10.40% |
| P/E ratio (TTM) | 26.06 | 74.15 |
| Forward P/E | 15.93 | 26.32 |
| EPS (TTM) | $12.09 | $2.09 |
| Dividend yield | 0.91% | 0.18% |
| Annual dividend | $2.88 | $0.28 |
| Revenue (latest FY) | $13.95B | $2.86B |
| Revenue growth (YoY) | +7.25% | +3.67% |
| Net income (latest FY) | $876.50M | $241.20M |
| Gross margin | 28.76% | — |
| Operating margin | 9.92% | 12.49% |
| Net margin | 6.28% | 8.45% |
| 52-week high | $341.80 | $166.25 |
| 52-week low | $244.52 | $81.22 |
| Distance from 52-week high | -7.81% | -6.78% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +9.24% | -12.33% |
| Average volume | 742.58K | 1.79M |
| Shares outstanding | 81.10M | 111.59M |
| Employees | 71,000 | 11,000 |
| Sector | Health Care | Industrials |
| Industry | Medical Specialities | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVTY has outperformed LH by 52.6 percentage points over the past year.
- Revvity trades at a higher earnings multiple (74.2x vs 26.1x trailing P/E).
- The two companies sit in different sectors: Labcorp in Health Care and Revvity in Industrials.
About Labcorp
LH stock →Labcorp Holdings Inc. provides laboratory services.
Health Care · Medical Specialities · 71,000 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
LH vs RVTY FAQ
Which is bigger, Labcorp or Revvity?
Labcorp (LH) is larger, with a market capitalization of $25.55B compared with $17.29B for Revvity (RVTY).
Which stock has performed better over the past year, LH or RVTY?
RVTY returned +65.81% over the past 12 months, compared with +13.22% for LH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, LH or RVTY?
LH has the lower trailing P/E at 26.1, versus 74.2 for RVTY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Labcorp or Revvity?
Labcorp has the higher yield at 0.91%, compared with 0.18% for Revvity.
Are Labcorp and Revvity in the same industry?
No. Labcorp is in the Health Care sector, while Revvity is in Industrials.